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Abstract 
Background: Health related quality of life measurements are vital elements of public health surveillance that 
uncover unmet health needs and predict the success of health interventions. We described health related quality 
of life measurements using the EuroQoL 5-dimension (EQ-VAS/EQ-5D) instrument and associated factors among 
patients with upper gastrointestinal bleeding (UGIB) and hepatic schistosomiasis at a rural health facility in the Albert 
Nile Basin, Uganda.
Methods and materials: This was a cross-sectional study at Pakwach Health Centre IV. Participants included adult 
inpatients and outpatients with a history of UGIB and ultrasound evidence of hepatic schistosomiasis. We evaluated 
and recorded each participant’s medical history, physical examination, laboratory tests results, ultrasound results, and 
endoscopy findings. We also recorded health related quality of life measurements using the EuroQoL 5-dimension 
instrument and derived disability weights from EQ-VAS and EQ-5D measurements. These were our dependent vari-
ables. Descriptive and inferential statistics were generated summarizing our findings.
Results: We found 103 participants had a history of upper gastrointestinal bleeding and hepatosplenic schistoso-
miasis. Sixty percent were between the ages of 30–49 years, 59% were females, 74% were farmers, 92% had spleno-
megaly, 88% had varices at endoscopy, 22% were medical emergencies with acute variceal upper gastrointestinal 
bleeding, and 62% had anemia. Measures of the different dimensions of health from 101 participants with patient 
reported outcomes revealed 77 (76%) participants experienced problems in self-care, 89 (88%) participants reported 
anxiety or depression, and 89 (88%) participants experienced pain or discomfort. The median EQ-VAS derived dis-
ability weights and median EQ-5D index-derived disability weights were 0.3 and 0.34, respectively. Acute upper 
gastrointestinal bleeding, praziquantel drug treatment, and age by decade predicted higher EQ-VAS derived disability 
weights (p value < 0.05). Under weight (Body mass index ≤ 18.5), acute upper gastrointestinal bleeding, ascites, age by 
decade, female gender, and praziquantel drug treatment predicted higher EQ-5D index- derived disability weights (p 
value < 0.05).
Conclusion: Adult patients with upper gastrointestinal bleeding and hepatic schistosomiasis from this primary 
health facility experience poor health and considerable health loss. Several factors predicted increased health loss. 
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Background
Dr. Warren in 1978 termed hepatic schistosomiasis, the 
“great neglected disease of the liver”. Hepatic schistoso-
miasis is an insidious disease that follows embolization of 
schistosoma eggs to the liver and portal system, leading 
to chronic inflammation, tissue injury, and progressive 
tissue fibrosis [1, 2]. Extensive periportal fibrosis, portal 
hypertension, varices, upper gastrointestinal bleeding, 
splenomegaly, and ascites are the hallmarks of advanced 
disease. Variceal upper gastrointestinal bleeding is the 
principal cause of morbidity, hospital admissions, and 
death among individuals with advanced hepatic schisto-
somiasis [3–8].
Chronic infection with S. mansoni is the only cause 
of hepatic schistosomiasis in Sub-Saharan Africa. In 
Uganda, the Albert Nile basin is a hot spot for S. mansoni 
infection [9, 10]. Studies show that between 30% to 50% 
of persons infected with S. mansoni from the Albert Nile 
basin had hepatic schistosomiasis [11–16]. Studies also 
show that 20% to 50% of adult patients diagnosed with 
hepatic schistosomiasis from an endemic area will also 
have portal hypertension, varices, variceal upper gastro-
intestinal bleeding at the time of first diagnosis [6, 8].
Currently Praziquantel mass drug administration is 
the main control intervention for schistosomiasis world-
wide. However, current evidence shows that Praziquantel 
mass drug administration has failed. Many Countries in 
Sub-Saharan Africa, including Uganda, did  not meet the 
World Health Organization’s goal for control and elimi-
nation of schistosomiasis by the year 2020 [17–20].
In Uganda, limited health financing has restricted 
schistosomiasis control measures to surveillance and 
Praziquantel mass drug administration [21, 22]. As a 
result, other aspects of control and care of patients with 
hepatic schistosomiasis seem neglected [23, 24]. Nowa-
days, there is no new data about the morbidity, mortality, 
and quality of life of patients with upper gastrointestinal 
bleeding and hepatic schistosomiasis from the Albert 
Nile basin. It is still not clear what health problems 
patients with upper gastrointestinal bleeding and hepatic 
schistosomiasis from the Albert Nile Basin face. We also 
do not know what perceptions they have about their 
health status as they seek healthcare.
Measures of the health status of individuals and popu-
lations are essential for any evidence-based health policy. 
Health related quality of life measurements are also vital 
elements of public health surveillance. Health related 
quality of life measurements can uncover unmet health 
needs and predict the success of health interventions 
[25, 26]. However, patients may experience unmet needs 
that based on their clinical profile or on various clinical 
factors.
Health related quality of life measurements are impor-
tant for successful control of hepatic schistosomiasis and 
upper gastrointestinal bleeding in the Albert Nile Basin. 
While clinical factors associated health related quality of 
life measurements are important for identifying unmet 
needs in clinical care.
We described health related quality of life measure-
ments using the EQ-5D tool and associated clinical fac-
tors among patients with upper gastrointestinal bleeding 
and hepatic schistosomiasis at a rural health facility in 
the Albert Nile Basin.
Materials and methods
This was a cross-sectional study that involved individu-
als attending the outpatient department and inpatients 
admitted acutely with severe upper gastrointestinal 
bleeding at the same health facility. The study was con-
ducted over 6  weeks between the months of July and 
August 2014 at Pakwach Health Centre IV, a government 
run primary health care facility located on the banks of 
the Albert Nile in northwestern Uganda. Pakwach Health 
Centre provides outpatient and inpatient health care ser-
vices to a population who are mainly fisher persons and/
or farmers. Epidemiological data suggests close to 50% of 
the populations served by this facility are infected with 
S. mansoni despite over a decade of Praziquantel chemo-
therapy. Medical records from the facility indicated about 
120 patients every year are admitted for acute upper 
gastrointestinal bleeding as a complication of chronic 
schistosomiasis.
Eligibility for study participation included written 
informed consent and ascent, all patients ≥ 12  years 
of age with a medical history of upper gastrointesti-
nal bleeding (past or current). We excluded pregnant 
women, HIV positive individuals, and any participant 
unable to have endoscopy for upper gastrointestinal 
bleeding. Pregnant women were excluded because of the 
restrictions of undertaking endoscopy. HIV patients were 
excluded from this study because ethical considerations 
(confidentiality and partner disclosure) and the fact that 
These factors probably represent key areas of health intervention towards mitigating increased health loss in this 
population.
Keywords: Health related quality of life measurements, Disability weights, Upper gastrointestinal bleeding, 
Schistosomiasis, EQ-5D/EQ-VAS
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another study was already recruiting patients with HIV 
and schistosomiasis [7, 27].
Upper gastrointestinal bleeding was defined by any 
lifetime history of hematemesis, melena, or hematoche-
zia. Participants at the outpatient’s department were sys-
tematically sampled and enrolled, while inpatients were 
consecutively recruited over 6 weeks. A detailed medical 
history that included socio-demographic data, exposure 
to schistosoma species or alcohol, treatment of schistoso-
miasis and time from the last treatment, history of upper 
gastrointestinal bleeding, and other relevant past medi-
cal history. Participants were examined for stigmata of 
chronic liver disease, and vital signs [7, 27].
Measures of health-related quality of life were obtained 
using the three-level European Quality of Life 5-Dimen-
sions (EQ-5D-Y) questionnaire and the visual analogue 
scale (EQ-VAS) from the EuroQol Group (EQ-5D™) [28, 
29]. The EQ-5D-Y is a multi-attribute utility instrument. 
The EQ-5D represents measures of personal well-being 
and this indicates opinions referenced to the general 
population. It has 5 dimensions that include mobility, 
self-care, usual activities, pain/discomfort, and anxiety/
depression. Each dimension is rated as a Likert scale 
from having no problems (level 1), some problems (level 
2), to extreme problems (level 3). The EQ-5D data was 
converted into an index of health (EQ-5D index) using 
crosswalk values from Zimbabwe in Stata [30]. These 
were considered the closest values to our study popula-
tion. Zimbabwe is found in south sub-Saharan Africa 
and schistosomiasis is endemic in Zimbabwe [31]. The 
economic and health indices are comparable. The EQ-5D 
index represents a measure of health from 0 for death 
to 1 for perfect health. The EQ-VAS is a visual analogue 
scale (VAS). The scale varies from 0, the worst imagina-
ble health state, to 100, the best imaginable health state. 
The EQ-VAS asks patients to indicate their overall health 
on a vertical visual analogue scale (0 to 100). This indi-
cates opinions referenced to an individual. The EQ-VAS 
and EQ-5D index were then transformed to disabil-
ity weights by the formulas [EQVAS-derived disability 
weights = 1 − (VAS/100)] and [EQ-5D index-derived dis-
ability weights = 1 − EQ-5D index] respectively. A disa-
bility weight is a weight factor that reflects the severity of 
the disease on a scale from 0 (perfect health) to 1 (equiva-
lent to death). Disability weights characterize the amount 
of health loss associated with specific health outcomes 
and are used to calculate years living with disability [28, 
29, 32–35].
Blood was analyzed generating 3-part hematology 
indices (using a compact Sysmex KX-21 hematology 
analyzer), hepatitis B and C viral blood serology results 
(obtained from commercially available rapid diagnostic 
test kits), and malaria antigen test results (from rapid 
diagnostic test kits). Stool microscopy was performed for 
Ova and urine for schistosomiasis using the urine circu-
lating cathodic antigen (CCA) test by Rapid Diagnostics. 
Trans-abdominal ultrasonography was performed by a 
trained sonographer according to the modified World 
Health Organization Niamey protocol using the SON-
OSTAR model SS8, a portable ultrasound with a 3.5 MHz 
convex probe. Upper digestive endoscopy was performed 
using a Pentax EPKi digital video processor and a Pentax 
9.8 mm video gastroscope after a local anesthetic (Xylo-
caine spray) by a gastroenterologist.
Data was transcribed from questionnaires and entered 
to Microsoft Access database. This was edited to ensure 
quality and exported to Stata version 16 (STATA Corp, 
Lakeway, College Station, Texas, USA).
Descriptive and inferential statistics were generated. 
These described the study population and measures of 
health-related quality of life (EQ-VAS, EQ-5D dimen-
sion, EQ-5D index, EQ-VAS-derived disability weights, 
and EQ-5D index-derived disability weights). Clini-
cal factors associated with EQ-VAS-derived disability 
weights, and EQ-5D index-derived disability weights 
were also explored. Categorical data were summarized 
as proportions with logit-transformed 95% confidence 
intervals. Continuous data were summarized as medians, 
interquartile range (IQR), and 95% confidence intervals. 
Medians and their 95% confidence intervals were gener-
ated using binomial method that makes no assumptions 
about the underlying distribution of the variable.
The strength and direction of relationship between 
EQ-5D dimensions, EQ-VAS, EQ-5D index, EQ-VAS-
derived disability weights, and EQ-5D index-derived dis-
ability weights were explored by Spearman’s correlation 
coefficient. This is summarized in a table format.
Multivariable analysis involved disability weights (EQ-
VAS-derived disability weights and EQ-5D index-derived 
disability weights) as the dependent variables. We des-
ignated clinical variables highlighted in Table 4 as inde-
pendent variables. These included the following variables 
age range, gender, occupations (farmer and fishermen), 
body mass index, ascites, splenomegaly, edema, jaundice, 
esophageal varices, acute upper gastrointestinal bleed-
ing, urine CCA for detection of schistosomiasis, hepati-
tis B surface antigen positivity, and previous treatment 
with praziquantel. Lasso in Stata 16 was used to select 
covariates and models. This process included cross vali-
dation, adaptive lasso, plug in’s for heteroskedasticity 
and homoskedasticity. We selected best regression mod-
els based on “Goodness of fit” after Lasso. Considering 
error variance, we performed heteroskedasticity linear 
regression for EQ-VAS-derived disability weights as the 
dependent variable. Homoskedasticity linear regression 
was performed for EQ-5D index-disability weights as the 
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dependent. The models were subject to population aver-
aged marginal effects analysis for all covariates in Stata. 
A significance level (p value < 0.05) was considered for all 
analysis, and confidence intervals or standard errors sup-
ported inference. We summarized these results as text, in 
tables, and as figures.
Ethics statement
This was a cross-sectional study that involved human 
participants. School of Medicine, Makerere University, 
Institutional review board, Kampala, Uganda (#REC 
REF2011-244), and the Uganda National Council for 
Science and Technology, Kampala, Uganda (UNCST 
approval #, HS 1620) approved this study. The study was 
conducted according to the principles expressed in the 
Declaration of Helsinki. Written informed consent was 
obtained from all participants.
Results
All participants had a past or current medical history of 
upper gastrointestinal bleeding. One fifth (23 participants 
out of 107 enrolled) presented as medical emergencies 
and were admitted with acute severe upper gastrointes-
tinal bleeding over the study period. We screened 324 
at the outpatient’s department over the same period and 
were able to enroll 84 patients with a past medical history 
of upper gastrointestinal bleeding.
Four out of the 107 participants did not have any 
evidence of hepatic schistosomiasis after ultrasonog-
raphy. Of 103 participants who had hepatic schistoso-
miasis, 2 participants had missing EQ-5DY records. The 
youngest participant was 25  years and the oldest was 
71 years. Sixty percent of our study population were aged 
30–49 years. The female-male ratio was 7 to 5. Most par-
ticipants were long-term residents of Pakwach. All par-
ticipants had frequent contact with the waters of the Nile 
(5–7 times a week) and nearly all were either fisherper-
sons or farmers by occupation. Among our participants, 
55% had a prior diagnosis of intestinal schistosomiasis, 
88% had ever received Praziquantel in the past, 8% had 
active infection at the time of enrolment, 92% had sple-
nomegaly on physical exam and 96% had moderate to 
severe periportal fibrosis and/or cirrhosis at ultrasonog-
raphy. All reported experiencing upper gastrointestinal 
bleeding with 96% reporting at least one lifetime episode 
of hematemesis, and 97% reporting past admission for 
upper gastrointestinal bleeding. No participant has ever 
had an endoscopy for upper gastrointestinal bleeding nor 
was on propranolol for prevention of recurrent variceal 
bleeding. Endoscopy was performed on all 107 partici-
pants during the study. Following endoscopy, we found 
86 had varices, 8 had both varices and peptic ulcers, and 
21 had peptic ulcers alone. Among the 103 participants 
who had hepatic schistosomiasis, 85 (83%) had varices 
and 18 (18%) had peptic ulcer disease. The clinical, labo-
ratory, ultrasound, and endoscopic characteristics of the 
103 participants, proportions and their 95% confidence 
intervals are summarized in Table 1.
Health related quality of life measurements
Measures of the 5 dimensions of health revealed 77 (76%) 
participants had some or extreme problems in self-care, 
89 (88%) participants reported some or extreme anxiety 
or depression, and 90 (89%) participants reported expe-
riencing some or extreme pain or discomfort. Only 37 
(37%) participants reported some or extreme problems in 
their mobility. However, 55 (55%) participants were able 
to undertake their usual activities without any problems 
(Fig. 1).
Table  2 summarizes calculated medians with confi-
dence intervals for the EQ visual analogue scale meas-
urements, EQ-5D utility index, EQ visual analogue 
scale derived disability weights, and EQ-5D utility index 
derived disability weights by different response variables. 
Covariates of interest had a median EQ visual analogue 
scale derived disability weight > 0.40 or a median EQ-5D 
utility index derived disability weight > 0.35.
Table 3 summarizes spearman’s rank correlation coef-
ficients and significance levels (p value < 0.05) for all the 
5 dimensions of the EQ-5D questionnaire, EQ visual 
analogue scale, EQ-5D utility index, EQ visual analogue 
scale derived disability weights, and EQ-5D utility index 
derived disability weights. EQ-5D index was positively 
and very strongly correlated with EQ-VAS (Spearman’s 
rank correlation, n = 101, Rho = 0.73, p value = 0.0001). 
A guide enabling inference of the correlation coefficients’ 
is provided within the table (interpretation of effect size) 
[36]. All parameters showed moderate to very large cor-
relations with each other (0.30 to 0.9).
Averaged marginal effects for all covariates for EQ visual 
analogue scale derived disability weights, and EQ‑5D 
utility index derived disability weights
Our results demonstrated that the probability of EQ-
VAS derived disability weights increased by 30 percent-
age points, 15 percentage points, 5 percentage points, 
and 7 percentage points when one experienced acute 
upper gastrointestinal bleeding, received praziquantel 
drug treatment, for every age by decade, and if one were 
of female gender respectively. While the probability of 
EQ-VAS derived disability weights decreased by 12 per-
centage points when one had Jaundice. All these changes 
were statistically significant (Table 4 and Fig. 2).
We also demonstrated that probability of EQ-5D index 
derived disability weights increased by 19 percentage 
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Table 1 Clinical, laboratory, ultrasound, and endoscopic characteristics of adult patients with hepatosplenic schistosomiasis and 
upper gastrointestinal bleeding
N =  103a Percentage Logit confidence limits




Age = 18–29 years 4 1 10
Age = 30–39 years 24 17 34
Age = 40–49 years 36 27 46
Age = 50–59 years 18 12 27
Age = 60–69 years 15 9 23
Age ≥ 70 years 3 1 9
Gender
Male 41 32 51
Female 59 49 68
Stayed in Pakwach for over 10 years
No 12 7 20
Yes 88 80 93
Contact with the Nile 5 to 7 times a week
No 1 0 7
Yes 99 93 100
Farmer
No 26 19 36
Yes 74 64 81
Fisherman
No 84 76 90
Yes 16 10 24
Hematemesis
No 4 1 10
Yes 96 90 99
Melena stool
No 55 46 65
Yes 45 35 54
Hematochezia
No 49 39 58
Yes 51 42 61
Schistosomiasis by positive stool test in the past
No 45 35 54
Yes 55 46 65
Praziquantel
No 12 7 20
Yes 88 80 93
Ever admitted for upper gastrointestinal bleeding
No 3 1 9
Yes 97 91 99
Ever received a blood transfusion
No 30 22 40
Yes 70 60 78
Splenomegaly (physical examination)
No 8 4 16
Yes 92 84 96
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Table 1 (continued)
N =  103a Percentage Logit confidence limits




No 83 74 89
Yes 17 11 26
Jaundice (physical examination)
No 89 82 94
Yes 11 6 18
Edema (physical examination)
No 88 80 93
Yes 12 7 20
Body mass index
≤ 18.5 17 10 25
18.5–24.9 79 70 86
25–29.9 4 2 11
Acute Severe variceal upper gastrointestinal bleeding
No 78 69 85
Yes 22 15 31
Fibrosis patterns
C 5 2 11
D 33 25 43
E 20 14 29
F 4 1 10
X 38 29 48
Spleen length ≥ 15 cm
No 40 31 50
Yes 60 50 69
Portal vein ≥ 13 mm
No 23 16 33
Yes 77 67 84
Ascites at ultrasound
No 85 77 91
Yes 15 9 23
Anemia grade(gm/dl)
< 6.5 19 13 28
6.5–7.9 11 7 20
8–9.4 15 9 23
9.5–10.9 17 10 25
≥ 11 38 29 48
Hepatitis B surface antigen positive
No 93 86 97
Yes 7 3 14
Hepatitis C antibody positive
No 74 64 81
Yes 26 19 36
Urine CCA 
No 92 85 96
Yes 8 4 15
Varices
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points, 10 percentage points, 19 percentage points, 03 
percentage points, 10 percentage points, and 12 percent-
age points when one was under weight (BMI ≤ 18.5), 
experienced acute upper gastrointestinal bleeding, one 
had ascites, for every age by decade, if one was of female 
gender, and had praziquantel drug treatment respectively. 
All these changes were statistically significant. All these 
changes were statistically significant (Table 4 and Fig. 3).
Discussion
Our study reports about EQ-5D derived health-related 
quality of life measurements from patients with hepatic 
schistosomiasis and upper gastrointestinal bleeding at a 
rural health facility in the Albert Nile basin. As far as we 
know, few studies have published EQ-5D outcome meas-
urements about patients with hepatic schistosomiasis. 
One study from Brazil and involved patients with S. man-
soni infection [34]. The other study from China involved 
patients with S. japonica infection [32]. Our study is 
unique because it is from Sub-Saharan Africa, where 90% 
of those who have schistosomiasis worldwide reside. It 
is also distinct because we focused only on patients with 
any life history of upper gastrointestinal bleeding at a 
rural primary health care facility in rural Africa. Primary 
health care research is essential for improved health pol-
icy [37].
The characteristics of our participants are not unique. 
Daily contact with the waters of the Nile, periportal 
fibrosis, splenomegaly, and varices were frequent in our 
study participants. This is in keeping with published 
literature [13, 16, 38–40]. The differential diagnosis of 
such a clinical profile is liver cirrhosis. However, liver 
cirrhosis was less likely because of the low prevalence 
of alcohol misuse and viral hepatitis B or C infections 
in our study [7]. We also found a low prevalence of stig-
mata of chronic liver disease including ascites, hepatic 
encephalopathy, and jaundice. These stigmata are more 
frequent in liver cirrhosis than hepatosplenic schistoso-
miasis [40, 41]. Peptic ulcer disease was infrequent and 
was less likely to cause upper gastrointestinal bleed-
ing among our participants. Regarding care, none of 
our participants had endoscopy, and no participant 
with varices was on propranolol to prevent recurrent 
variceal bleeding before enrollment into the study. 
Table 1 (continued)
N =  103a Percentage Logit confidence limits
Lower limit (5%) Upper 
limit 
(95%)
No 17 11 26
Yes 83 74 89










9.90% 8.91% 11.88% 13.86%
MOBILITY SELFCARE USUAL ACTVITY PAIN/DISCOMFORT ANXIETY/ DEPRESSION 
EQ-5D-3L
No problems Some problems Unable/Extreme problems
Fig.1 Response distribution of EQ5D-3 level domains for participants with upper gastrointestinal bleeding and schistosomiasis (n = 101)
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Table 2 Medians (95% confidence intervals) of EQ-VAS, EQ-5D index, and derived disability weights by different clinical factors





Median 95% CI Median 95% CI Median 95% CI Median 95% CI
All participants 101 70 60, 70 0.59 0.59, 0.62 0.30 0.30, 0.40 0.34 0.31, 0.35
Age, years
18–29 4 75 70, 90 0.67 0.59, 0.73 0.25 0.10, 0.30 0.26 0.21, 0.35
30–39 25 70 60, 80 0.62 0.52, 0.62 0.30 0.20, 0.40 0.31 0.31, 0.38
40–49 36 65 50, 70 0.62 0.59, 0.62 0.35 0.30, 0.50 0.31 0.31, 0.35
50–59 18 50 40, 80 0.59 0.09, 0.73 0.50 0.20, 0.60 0.38 0.31, 0.53
60–69 15 60 50, 70 0.52 0.19, 0.62 0.40 0.30, 0.50 0.40 0.31, 0.50
≥ 70 3 30 20, 60 − 0.13 − 0.18, − 0.13 0.70 0.40, 0.80 0.78 0.77, 0.78
Men 40 70 50, 80 0.62 0.59, 0.66 0.30 0.20, 0.50 0.31 0.30, 0.35
Women 61 60 50, 70 0.55 0.52, 0.62 0.40 0.30, 0.50 0.36 0.31, 0.40
Fisherman 14 70 50, 80 0.68 0.58, 0.79 0.30 0.20, 0.50 0.33 0.21, 0.42
Farmer 76 70 60, 70 0.65 0.62, 0.70 0.30 0.30, 0.40 0.35 0.31, 0.38
Jaundice
No 90 70 60, 70 0.62 0.59, 0.62 0.30 0.30, 0.40 0.31 0.31, 0.35
Yes 11 60 40, 70 0.52 − 0.16, 0.59 0.40 0.30, 0.60 0.40 0.34, 0.68
Edema
No 90 70 60, 70 0.62 0.59, 0.62 0.30 0.30, 0.40 0.31 0.31, 0.35
Yes 11 40 30, 50 0.15 − 0.18, 0.62 0.60 0.50, 0.70 0.48 0.31, 0.77
Splenomegaly
No 8 65 20, 90 0.57 − 0.35, 0.80 0.35 0.10, 0.80 0.36 0.17, 0.99
Yes 89 70 60, 70 0.62 0.59, 0.62 0.30 0.30, 0.40 0.32 0.31, 0.35
Tense ascites (exam difficult) 4 30 10, 40 0.12 − 0.59, 0.15 0.70 0.60, 0.90 0.51 0.48, 1.15
Praziquantel
No 11 80 70, 90 0.66 0.52, 0.80 0.2 0.10, 0.30 0.30 0.17, 0.34
Yes 90 60 50, 70 0.59 0.52, 0.62 0.4 0.30, 0.50 0.35 0.31, 0.40
Body mass index ≤ 18.5
No 84 70 60, 70 0.62 0.59, 0.62 0.3 0.30, 0.40 0.31 0.31, 0.35
Yes 17 50 40, 70 0.52 1.66, 0.62 0.5 0.30, 0.60 0.41 0.31, 0.78
Liver fibrosis pattern score
C 5 60 50, 90 0.59 − 0.13, 0.70 0.4 0.10, 0.50 0.35 0.21–0.78
D 34 70 60, 80 0.62 0.55, 0.66 0.3 0.20, 0.40 0.31 0.30, 0.35
E 21 70 50, 80 0.62 0.52, 0.62 0.3 0.20, 0.50 0.32 0.31, 0.40
F 3 50 50, 80 0.59 0.52, 0.62 0.5 0.20, 0.50 0.36 0.31, 0.40
X 38 60 50, 70 0.59 0.24, 0.62 0.35 0.31, 0.42 0.35 0.31, 0.42
Ascites by ultrasound
No 87 70 60, 70 0.62 0.59, 0.62 0.3 0.30,0.40 0.31 0.31, 0.35
Yes 14 40 30, 50 0.15 − 1.26, 0.52 0.6 0.50, 0.70 0.48 0.40, 0.77
Varices
No 18 70 50, 80 0.6 0.52, 0.67 0.3 0.20, 0.50 0.33 0.30, 0.40
Yes 83 70 50, 70 0.59 0.52, 0.63 0.3 0.30, 0.50 0.35 0.31, 0.36
Acute upper gastrointestinal bleeding
No 79 70 70, 80 0.62 0.59, 0.62 0.3 0.20, 0.30 0.31 0.31, 0.35
Yes 22 40 30, 50 0.2 − 0.13, 0.59 0.6 0.50, 0.70 0.45 0.36, 0.68
Urine CCA 
No 93 70 60, 70 0.59 0.52, 0.62 0.3 0.30,0.40 0.35 0.31, 0.36
Yes 8 65 0, 80 0.6 − 0.13, 0.62 0.35 0.20, 1.0 0.33 0.31, 0.78
Anemia grade (gm/dl)
Page 9 of 13Opio et al. J Patient Rep Outcomes           (2021) 5:112  
Current care guides recommend endoscopy for all with 
upper gastrointestinal bleeding and/or propranolol for 
those with upper gastrointestinal bleeding and varices 
[4, 42, 43].
Evaluation of EQ-5D primary data showed that our 
participants reported more problems in all the five 
measured health domains (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) 
than the study by Nascent et al. In addition, the mean 
and median EQ-VAS scores in our study were also 
lower than the study by Nascent et  al. [34]. These dif-
ferences were greatest for the domains of welfare, and 
anxiety/depression This could be explained by dissimi-
larities in disease severity and access to better health 
care services.
UGIB-upper gastrointestinal bleeding, 95CI – 95% confidence intervals
Table 2 (continued)





Median 95% CI Median 95% CI Median 95% CI Median 95% CI
< 6.5 20 50 40, 70 0.6 0.29, 0.64 0.5 0.30, 0.60 0.40 0.36, 0.71
6.5–7.9 12 50 31, 69 0.56 0.47, 0.55 0.5 0.31, 0.69 0.44 0.35, 0.53
8.0–9.4 15 60 50, 80 0.65 0.60, 0.70 0.4 0.20, 0.50 0.35 0.31, 0.40
9.5–10.9 16 65 55, 80 0.72 0.62, 0.79 0.35 0.20, 0.45 0.28 0.21, 0.38
≥ 11.0 38 75 70, 80 0.7 0.69, 0.70 0.25 0.20, 0.30 0.31 0.30, 0.31
Hepatitis B surface antigen positive
No 94 60 50, 70 0.65 0.62, 0.70 0.4 0.30, 0.50 0.35 0.31, 0.38
Yes 7 80 70, 87 0.7 0.65, 0.79 0.2 0.13, 0.30 0.31 0.21, 0.35
Table 3 Spearman’s rank correlation coefficients of EQ-5 domains, EQ-VAS, EQ-5D index and derived disability weights
* Significance level p < 0.05
















Usual activities, 0.5849* 0.4725* 1
Pain/discom-
fort
0.4721* 0.3898* 0.4550* 1
Anxiety/
depression
0.3364* 0.3429* 0.2253 0.3151* 1
EQ-VAS − 0.6308* − 0.4928* − 0.6051* − 0.4300* − 0.4162* 1
EQ-5D index − 0.7553* − 0.7494* − 0.7160* − 0.6270* − 0.5922* 0.7288* 1
EQ-VAS disabil-
ity weight
0.6308* 0.4928* 0.6051* 0.4300* 0.4162* − 1 − 0.7288* 1
EQ-5D disabil-
ity weight
0.7553* 0.7494* 0.7160* 0.6270* 0.5922* − 0.7288* − 1 0.7288* 1
# Correlation coefficient Interpretation of effect size
.90 to 1.00 Nearly, practically, or almost: perfect, distinct, infinite
.70 to .90 Very large, very high, huge
.50 to .70 Large, high, major
.30 to .50 Moderate, medium
.10 to .30 Small, low, minor
.00 to .10 Trivial, very small, insubstantial, tiny, practically zero
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Jia et  al. reported similar findings for dimensions of 
pain/discomfort, anxiety/ depression, and mobility. How-
ever, differences are apparent for dimensions of usual 
activities and self-care. The high prevalence of ascites 
from that Jia et al. could explain this variance [32].
Our EQ-5D measurements (index and VAS) are com-
parable with a systematic review about health state esti-
mates about diseases [44]. From our study, the EQ-5D 
index and EQ-5D VAS were strongly positively corre-
lated. This indicates that using Zimbabwe cross talk val-
ues did not adversely impact our EQ-5D index estimates. 
The average disability weights EQ-5D VAS derived dis-
ability weights, and EQ-5D index derived disability 
weights from our study population were 0.3 and 0.34 
respectively. This suggests that our participants experi-
enced poor health 4  months out of 12  months for each 
survived life year. The “Global Burden of Disease Study 
2017” has reported disability weights for hematemesis, 
severe anemia, and ascites from schistosomiasis as 0.325, 
0.149, and 0.144 respectively [35]. Nearly all our patients 
reported a history of hematemesis.  The average EQ-5D 
VAS derived disability weights, and EQ-5D index derived 
disability weights from our study population were 0.3 
and 0.34 respectively. These are like what are reported by 
the “Global Burden of Disease Study 2017”. On the other 
hand, disability weights for severe anemia, and ascites 
from the “Global Burden of Disease Study 2017” are 3 
to 4 times  less than what we found from our study. The 
“Global Burden of Disease Study 2017” did not provide 
disability weights for acute variceal upper gastrointestinal 
bleeding [35]. The implications of  some of these findings 
have been discussed by Jia et  al. [32]. We echo similar 
views.
Factors associated with EQ-5D VAS derived disabil-
ity weights included acute upper gastrointestinal bleed-
ing, Praziquantel drug treatment, age range by decade, 
and female gender. While factors associated with EQ-5D 
index derived disability weights included underweight 
(BMI ≤ 18.5), acute upper gastrointestinal bleeding, 
ascites, age range by decade, female gender, and Prazi-
quantel drug treatment. Jia et  al., reported that EQ-5D 
VAS derived disability weights were associated with age, 
Table 4 Summarizes the average marginal effects for EQ-VAS 
derived disability weights and EQ-5D derived disability weights 
by different covariates after linear regression and marginal 
analysis
Marginal analysis enables examination of the impact of variable x (covariates) on 






Model 1—EQ-VAS derived disability weights
Acute upper gastrointestinal bleeding 0.30 0.23, 0.37 0.001
Praziquantel 0.15 0.07, 0.22 0.001
Age range by decade 0.05 0.02, 0.07 0.001
Body Mass Index ≤ 18.5 0.05 − 0.05, 0.14 0.326
Female gender 0.07 0.00002, 0.13 0.050
Jaundice − 0.12 − 0.20, − 0.04 0.004
Model 2—EQ-5D derived disability weights
Body mass index ≤ 18.5 0.19 0.05, 0.33 0.009
Acute upper gastrointestinal bleeding 0.10 0.02, 0.18 0.018
Ascites 0.19 0.05, 0.32 0.010
Age range by decade 0.03 0.003, 0.06 0.031
Female gender 0.10 0.03, 0.18 0.006
Praziquantel 0.12 0.04, 0.20 0.003
Farmers 0.07 − 0.005, 0.14 0.069
World Health Organization Anemia 
grade
− 0.007 − 0.04, 0.03 0.690
Fig. 2 Average marginal effects for different covariate on EQ-VAS 
derived disability weights
Fig. 3 Average marginal effects for different covariate on EQ-5D 
index derived disability weights
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impaired work capacity, depression, anxiety, ascites, and 
active hepatitis B infection. We found similar findings for, 
depression/anxiety, ascites, and active hepatitis B infec-
tion (Additional file  1). The negative coefficient in the 
model could be explained by the inadvertent exclusion of 
patients with hepatitis B virus decompensated liver dis-
ease i.e., jaundice, Additional file 1.
To the best of our knowledge, no study has directly 
linked the occurrence of acute upper gastrointestinal 
bleeding and schistosomiasis to higher disability. What 
is known is that acute upper gastrointestinal bleeding 
is the main reason for hospitalization and death among 
patients with schistosomiasis due to S. mansoni [5, 6, 45, 
46]. It therefore stands to reason that preventing acute 
upper gastrointestinal bleeding could decrease health 
loss in this population [8]. In the same way, address-
ing ascites and praziquantel adverse drug effects in this 
population could also decrease health loss. These asser-
tions are supported by published research which shows 
that many acute illnesses requiring hospitalization are 
usually associated with increased disability. Preventing 
hospitalization decreases disability or health loss [47]. 
Acute upper gastrointestinal bleeding can be prevented 
through secondary prophylaxis with drugs, bands, and 
shunts. Ascites can be treated/prevented with drugs and 
paracentesis.
Praziquantel treatment has been associated with 
adverse drug effects including occurrence recurrent and 
acute upper gastrointestinal bleeding in this population 
[48, 49]. Mitigating these adverse effects could improve 
health related quality of life measurements in this study 
population.
One retrospective case series reported a significantly 
higher proportion of females presented with upper gas-
trointestinal bleeding due to varices than males (39.4% 
vs. 23.6%, p < 0.001) [50]. Research from this study pop-
ulation showed that female gender was a predictor of 
recurrent upper gastrointestinal bleeding [7]. We pro-
pose that there is a link between female gender, recurrent 
upper gastrointestinal bleeding, and disability. Nascent 
et  al., reported that median EQ-5D index values from 
their study was significantly lower among females and 
patients with comorbidities [34]. Underweight (body 
mass index ≤ 18.5) has been associated with poor self-
rated health [51].
Our study has limitations. Our sample size is small, and 
this was a single Centre cross sectional study at a rural 
primary health care facility. This makes our results less 
conclusive for several reasons. Small studies are likely 
to overestimate the magnitude of association. Further-
more, we could have inadvertently excluded individuals 
in this community that do not have access to this facil-
ity for any reason including death due to acute upper 
gastrointestinal bleeding. This is evident from the direc-
tion of association between jaundice and disability.
We also acknowledge that our use of the EQ-5D (a 
generic quality of life measurement tool) and the lack 
of population-specific crosstalk data from the Albert 
Nile basin could have made our EQ-5D index-disability 
measurements less precise. The EQ-5D index could have 
introduced an exogenous source of variance. Neverthe-
less, we found many similarities between our study and 
what has been published by others about health related 
quality of life measurements from patients with hepatic 
schistosomiasis [32, 34, 35, 52]. This suggests that our 
results might be more robust than we demonstrate.
Conclusions
Adult patients with upper gastrointestinal bleeding and 
hepatic schistosomiasis from this rural primary health 
facility in sub–Saharan Africa experienced poor health 
and substantial health loss. These findings are compa-
rable with studies from china and brazil about hepatic 
schistosomiasis. We also identified several factors asso-
ciated with individual health loss among participants 
with upper gastrointestinal bleeding and schistosomia-
sis. These factors probably represent unmet health needs 
and may point out potential areas for health interven-
tion. Even so, more research is needed to confirm these 
findings.
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